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Abstract: Temozolomide (TMZ) is the standard first line treatment for malignant glioma, 
reaching “blockbuster” status in 2010, yet it remains the only drug in its class. The main 
constraints on the clinical effectiveness of TMZ therapy are its requirement for active DNA 
mismatch repair (MMR) proteins for activity, and inherent resistance through O6-methyl 
guanine-DNA methyl transferase (MGMT) activity. Moreover, acquired resistance, due to 
MMR mutation, results in aggressive TMZ-resistant tumour regrowth following good 
initial responses. Much of the attraction in TMZ as a drug lies in its PK/PD properties: it is 
acid stable and has 100% oral bioavailability; it also has excellent distribution properties, 
crosses the blood-brain barrier, and there is direct evidence of tumour localisation.  
This review seeks to unravel some of the mysteries of the imidazotetrazine class of 
compounds to which TMZ belongs. In addition to an overview of different synthetic 
strategies, we explore the somewhat unusual chemical reactivity of the imidazotetrazines, 
probing their mechanisms of reaction, examining which attributes are required for an active 
drug molecule and reviewing the use of this combined knowledge towards the development 
of new and improved anti-cancer agents. 
Keywords: azolotetrazinone; temozolomide; mitozolomide; MGMT; DNA mismatch repair; 
DNA alkylation 
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1. Introduction 
Imidazotetrazines are a class of bicyclic aromatic heterocycles, exemplified by the DNA methylating 
agent, temozolomide (Temodar®, Temodal®, TMZ, 1a). Notable previous reviews of the imidazotetrazines 
have focused on the development of TMZ [1,2] and the clinical properties and significance of  
TMZ [3,4]. The last detailed analysis of imidazotetrazine chemistry appeared in 1990 [5]. TMZ 
entered clinical trials in 1985 and since its release to the market by Schering-Plough in 1999 [6],  
has been widely used in combination with radiotherapy as the standard first-line treatment for 
malignant glioma (glioblastoma multiforme, grade IV astrocytoma). Somewhat serendipitously, as a 
drug it has excellent features: it is a stable solid which is also acid stable, allowing for 100% oral 
bioavailability, so administration is straightforward in comparison with many anticancer drugs. 
Absorption is rapid, with peak plasma concentration achieved within 0.33–2 h. Biodistribution is 
excellent (Vd 17 Lmí2) [7], and PET studies using 11C-labelled prodrug have provided direct evidence 
of blood-brain barrier penetration [8]. In 2010, TMZ reached blockbuster drug status, yet despite this 
impressive record it remains the only member of its class in the clinic. In this review we will explore 
the reasons for this and what makes TMZ special, along with surveying current efforts to achieve new 
effective drugs in this class. 
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The early history of imidazotetrazinone pharmacology indicated a considerable activity cliff with 
only a very small number of analogues exhibiting anticancer activity in vitro or in vivo. The 3-haloethyl 
analogues had good activity, the 3-methyl was of moderate effectiveness but other analogues, as 
exemplified by the 3-ethyl, were inactive (Table 1) [9]. The solution to this conundrum and the vision 
to design active new analogues arose from detailed definition of the mechanism of prodrug activation 
using kinetic NMR experiments. Indeed, TMZ entered clinical trials before the final details of prodrug 
activation chemistry were elucidated. 
Table 1. Activity of various TMZ analogues against TLX5 lymphoma implanted s.c. in 
CBA/CA mice. Adapted with permission from reference [9]. Copyright (1987) American 
Association for Cancer Research. 
 
N N
N
N
N
CONH2
O
R
1
 R Dose mg/kg/day T/C b % 
1a CH3 (TMZ) 
160 151 
80 a 154 
40 a 181 
1b (CH2)2Cl (MTZ) 
40 458 
16 a 302 
1c CH2CH3 (ETZ) 
640 123 
80 a 111 
1d (CH2)2Br 160 137 
1e (CH2)2CH3 320 103 
1f (CH2)2OCH3 320 98 
1g (CH2)3Cl 320 108 
1h CH2CHClCH2Cl 320 103 
1j CH2CH=CH2 320 97 
1k CH(CH3)CH2CH3 320 83 
1m (CH2)5CH3 320 103 
a Divided dose schedules; b treated versus control. 
2. Mechanism of Action 
TMZ (1a) is in fact a prodrug of a prodrug and its aqueous chemistry is typical of imidazotetrazine 
compounds (Scheme 1). Under neutral or alkaline conditions it undergoes hydrolytic ring opening, 
under purely chemical control, to give the open chain triazene MTIC (2) as the first significant 
intermediate. The prodrug dacarbazine (DTIC, 3), which is used to treat a number of cancers including 
malignant melanoma, also shares this intermediate but in contrast requires hepatic demethylation via 
CYP450 oxidation and loss of formaldehyde to release MTIC [10]. This activated intermediate 
fragments to liberate AIC (4) and methyl diazonium ions 5 which then react with nucleophilic sites on 
DNA; it is the interaction of this methylated DNA with various DNA repair pathways that elicits the 
cell killing response. 
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Scheme 1. Prodrug activation of TMZ. 
 
Methylation of DNA occurs at a number of nucleophilic sites, the majority of which appears at 
guanine-N7 (70%) with a further 9% at adenine-N3 [1]. This N-methylation, however, is of no 
therapeutic value since the lesions are efficiently handled by base excision repair (BER) enzymes [11]; 
the anti-cancer activity of TMZ is solely attributed to the small fraction (5%) of methylation which 
occurs at guanine-O6. 
The therapeutic effect of TMZ is dependent on the presence of DNA mismatch repair (MMR) 
proteins. O6-Methylguanine results in a mispairing during replication as it preferentially forms a 
wobble base pair with thymine. This is recognised by MMR which triggers a response; that is, T is 
identified, removed but then replaced with another T. Futile cycles of excision/repair result in 
depletion of dTTP, ultimately leading to long-lived strand breaks and cell death [1,11,12]. The GO6 
methyl adduct can, however, be repaired by O6-methylguanine-DNA methyltransferase (MGMT), 
resulting in active resistance to TMZ in tumours in which MGMT is proficient. Acquired resistance to 
TMZ can be brought about by mutations in MMR, in particular the MSH6 subunit that recognises GO6 
modifications, or enhanced MGMT activity through promoter hypomethylation [13]. The action of 
MGMT is not enzymatic; the protein is consumed stoichiometrically during the repair process and as 
such, inactivation of the protein can have a beneficial effect. With tumour cells high in MGMT levels, 
pre-treatment with inactivators such as O-benzylguanine has been shown to enhance the in vitro and  
in vivo activity of TMZ [14]. Several combination studies with inhibitors of alternative repair 
processes have also been carried out and are reviewed elsewhere [11]. 
It is evident that in order for a tumour to be responsive to TMZ treatment, it must be deficient in 
MGMT whilst also proficient in MMR; absence of the latter results in a tolerant phenotype whilst 
presence of MGMT impedes therapy regardless of MMR status. 
3. Elucidation of Prodrug Activation 
The key experiment attempted to identify intermediates in the prodrug activation pathway by  
time-dependent NMR spectroscopy [15–17]. Although the experiment was too insensitive to detect any 
reactive intermediates directly, the NMR data proved crucial to understanding the prodrug activation 
mechanism. When TMZ was reacted in a phosphate buffer/D2O system at pD = 7.8, designed to mimic 
physiological pH, the methyl group bearing products (methanol and methyl phosphate) showed 
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significant loss of 1H signal and the emergence of complex multiplet signals typical of 1H–2H geminal 
coupling in the products (Figure 1A). It appeared that during the reaction, all three 1Hs of the TMZ 
methyl became freely exchangeable with the solvent so that the 1H/2H ratio in the final products of 
methyl group transfer reflected the relative proportions of 1H and 2H in the H2O/D2O solvent mixture. 
Furthermore, at high pH it proved possible to simultaneously observe MTIC (2) which did not exhibit 
methyl group 1H/2H exchange as well as its reaction products where similar 1H/2H exchange was 
evident (Figure 1B). The final experiment to confirm the diazonium intermediate involved condensing 
diazomethane (6) into the H2O/D2O systems whereupon the products of 1H/2H exchange again 
appeared (Figure 1C); indeed this process was similar to the published synthesis of isotopically-labelled 
diazomethane [18]. These experiments established the position of methyldiazonium as the ultimate 
electrophile in the prodrug activation mechanism of TMZ (Scheme 1). 
Figure 1. Reaction of TMZ, MTIC and CH2N2 in D2O systems. (A) Products of reaction of 
TMZ with phosphate buffer pD = 7.8 showing deuterium incorporation into methanol and 
methyl phosphate; (B) MTIC in Na2CO3 (10% in D2O) showing the intact isotopic 
configuration of the MTIC methyl and deuterium incorporation into the methanol product 
of hydrolysis; (C) Products of condensing diazomethane into Na2CO3 (10% in D2O) [15–17]. 
 
3.1. The Chemistry of MTZ and ETZ 
The realisation that diazonium ions were formed by triazenes allowed explanation of the activity 
and inactivity of other imidazotetrazine analogues. MTZ as the more potent (but myelosuppressive), first-
generation imidazotetrazine prodrug was shown to be activated predominantly through the 
chloroethyltriazene analogue of MTIC [19,20]. The chloroethyldiazonium ions 5b that would be 
derived this way have a complex aqueous chemistry involving elimination and hydrolysis pathways 
that was extensively investigated for reactive intermediates generated by the chemically-related diazonium 
prodrugs, the chloroethyl nitrosoureas [21]. NMR experiments with MTZ confirmed the complexity of 
this chemistry in the context of the imidazotetrazines (Figure 2, Scheme 2). The 1H-NMR spectra were 
more complex than for TMZ and the reaction took longer to reach completion. As expected, 
chloroethanol (7) and alkylated phosphates 8 were the principal aliphatic products; in the aromatic 
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region, the major product was AIC (4) with a trace of 2-azahypoxanthine (AHX, 9), the product of 
intramolecular trapping of the TMZ precursor diazo-IC 10, and at least two other modified imidazoles. 
In contrast to TMZ, there was no evidence of deuterium incorporation into any products (Figure 2, 
Scheme 2c), neither was there evidence of elimination to vinyl chloride 11 (Scheme 2d). These 
observations are significant as they suggest a role for the chlorine atom in diazonium ion stability, for 
example by formation of a full or partial chloronium ion 12. Other DNA reactivity considerations also 
point to the involvement of a chloronium intermediate [22]. 
Figure 2. Reaction of MTZ with phosphate buffer pD = 7.8, 37 °C. (A) 1H-NMR spectrum 
after 14 days; (B) The same sample spiked with authentic chloroethanol (7). 
 
Interestingly, reaction in lower alcohols and acetonitrile at elevated temperatures followed a  
retro-cycloaddition route, as evidenced by detection of degradation products of diazo-IC, i.e., AHX, 
and chloroethyl isocyanate (13b) (Scheme 2b). The trace of AHX produced in the aqueous buffer 
system showed that this route, although not preferred, exists in aqueous systems, giving credence to 
early reports of MTZ as a carbamoylating agent [23]. Incidentally, the trifluoroethyl analogue only 
reacted by the retro-cycloaddition route in aqueous systems (vide infra, Scheme 4). 
Scheme 2. The aqueous chemistry of MTZ. 
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A great anomaly of the early compounds was the inactivity of the ethyl and higher alkyl analogues 
(vide supra, Table 1). In reaction with DNA it was impossible to detect GN7 alkylation sites, even at 
very high dose (5 mM) of ethazolastone (ETZ, 1c) and there was no in vitro or in vivo antitumour 
activity (Figure 3) [24]. The reason for this becomes apparent when the fates of ethyldiazonium ions 
are considered (Scheme 3) [25]. 
Figure 3. Comparison of reaction of ETZ and TMZ with DNA, showing the unreactivity of 
ETZ up to 5 mM, sites of GN7 alkylation produced in the 276-bpBamHI-Sal1 fragment of 
pBR322, by the piperidine cleavage method. Adapted from reference [24]. 
 
Scheme 3. The aqueous chemistry of ETZ. 
 
The NMR experiment in deuterated buffer was relatively uncomplicated (Figure 4). In this case the 
experiment was conducted in a two phase D2O/CDCl3 system. Deuterium incorporation was not 
detected in any products so, as with MTZ, the diazoalkane equilibration with 6c did not occur. Ethanol 
and ethylphosphate were confirmed as the major reaction products in the D2O layer. In the CDCl3 
layer, a singlet peak appeared at 5.3 ppm in the 1H spectrum. Reaction with Br2 and subsequent spiking 
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with authentic dibromoethane identified the by-product as ethene: a result of elimination of 
ethyldiazonium 5c. This implies that the fate of ethyldiazonium is either immediate nucleophilic 
substitution or rapid elimination to ethene without time for diazoethane equilibration. In the former 
case, the incipient electrophile may be too short lived to effectively locate a reaction site on DNA, 
while the latter route results in drug inactivation by elimination. 
Figure 4. 1H-NMR investigation of the reaction of ETZ with phosphate buffer  
(pH 7.8) in a two phase system (D2O/CDCl3). Spectra A–C CDCl3 layer, spectra D–G, D2O 
layer. (A) At the end of the imidazotetrazine hydrolysis reaction identifying the putative 
ethene peak; (B) after addition of Br2, the arrow indicates the position of a new peak; (C) 
sample of spectrum B after adding authentic dibromoethane; (D) at the end of the 
imidazotetrazine hydrolysis reaction; (E–G) sample of spectrum D after sequentially 
spiking with authentic AIC, ethylphosphate and ethanol (note the shift in the AIC signal 
after adding the acidic ethyl phosphate). 
 
The need to block elimination led first to analogues lacking hydrogen atoms in the ȕ-position of the 
side chain such as the 3-furfuryl and 3-trifluoroethyl 1n (Scheme 4) [25]. Of these, the trifluoroethyl 
analogue showed reasonable activity in the NCI60 cell line panel, with mean GI50 = 10.7 µM  
(log range = 2.35) compared with MTZ (79 µM, log range = 0.96), with a distinctly different 
pharmacological profile from MTZ (p = í0.347). Interestingly, a sample dissolved in DMSO showed 
clean retro-cycloaddition to give AHX and trifluoroethylcarbamic acid on standing overnight at room 
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temperature. In a capricious turn of fate, investigation of the aqueous prodrug activation mechanism by 
1H-, 31P- and 19F-NMR showed a complex mixture of products that included AHX and a mixture of at 
least nine fluorine containing compounds of which trifluoroethanol and trifluoroethylamine were 
components [25]. The aliphatic portion of the product mixture spectra (1H and 19F) could be replicated 
by reaction of trifluoroethylisocyanate (13n) with buffer. This is a contrast to MTZ where heating in a 
non-aqueous system was required to effect the retro-cycloaddition and indicates that the balance 
between retro-cycloaddition and hydrolysis at C4 is determined by the electron withdrawing effect of 
the 3-substituent. 
Scheme 4. The aqueous fate of the 3-trifluoroethylanalogue 1n. 
 
4. Kinetic Considerations 
The data in Scheme 1 highlight two kinetic parameters key to the design of new agents. The first is 
the rate of addition of water (or hydroxide ion) to initiate the ring-opening reaction. The prodrug itself 
must be sufficiently stable to allow uptake and distribution without significant hydrolysis. The second 
is the reactivity of the latent electrophile. 
4.1. Prodrug Activation Kinetics 
An important property of the imidazotetrazines is the contrast of robust acid stability with rapid 
alkaline hydrolysis (Figure 5); the slow hydrolysis at low pH confers acid stability and the convenience 
of oral dosing [16]. The pH-dependence of this reaction also influences distribution of the prodrug 
around the body: hydrolysis kinetics at pH 7.4 match closely the uptake rate (peak plasma 
concentration after 30 min) and metabolic half-life (t½ = 1.29 h) in patients [1,9]. If the aqueous 
lifetime were too short, the prodrug would be inactivated long before it were able to reach its  
sub-cellular target; too long it could be metabolised and excreted without taking effect. The pH 
dependence of TMZ and MTIC hydrolysis are complementary, so that it is only around neutral pH that 
the whole reaction process from prodrug activation to methyl group transfer occurs effectively, indeed 
MTIC and similar triazenes may be prepared by alkaline hydrolysis of their imidazotetrazines [20]. 
Superficially, imidazotetrazine activation is hydrolysis of a carbonyl compound with water or 
hydroxide ion attacking at C4, so that both acid and base catalysed reactions would be expected, in 
common with other carbonyl group reactions. The reason for the absence of the acid catalysed variant 
is the presence of the weakly basic imidazole N7. 15N-NMR experiments showed that the resonance of 
N7 was shifted and inverted in the presence of TFA, indicating that it carried a proton and was also, 
formally, the site of the positive charge (Figure 6) [26]. Since protonation occurs at a distant site, it is 
not able to activate the 4-carbonyl group to nucleophilic attack. The site of protonation at N7  
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was independently determined in the X-ray crystal structure of the salt TMZ·HCl·2H2O (vide infra, 
Figure 9) [27]. 
Figure 5. pH Dependence of the pseudo-first order rate constants for hydrolysis of TMZ 
and MTIC. Adapted from reference [16]. 
 
Figure 6. 15N-NMR spectra of TMZ. (A) 15N{1H} in DMSO-d6; (B) with full 1H nOe in 
TFA. Both experiments were acquired in the presence of Cr(acac)3 and referenced to 
external CH3NO2 [26]. 
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In addition to pH, the aqueous reactivity of imidazotetrazines generally is also dependent on the 
nature of the 3-substituent, such that the rate of hydrolysis is increased by electron withdrawing  
groups [20], notwithstanding the ability of powerfully electron withdrawing groups to switch the 
mechanism away from hydrolysis to the retro-cycloaddition reaction. 
4.2. Ultimate Electrophile Lifetime 
The other significant kinetic parameter is the lifetime of the ultimate electrophile released from the 
prodrug. Hydrolysis of methyldiazonium in a purely chemical system has t½ = 0.39 s [28]. Again, a 
sub-optimal value detracts from clinical effectiveness: ethyldiazonium eliminates or reacts with water 
before it has time to encounter a reactive nucleic acid target site [25], while longer-lived intermediary 
electrophiles such as chloronium achieve clinical efficacy [29]. For TMZ, these clinically-useful, if not 
formally optimized, pharmacokinetic properties were achieved serendipitously. 
5. Temozolomide Co-Crystals 
Drug stability, solubility and formulation are important factors when considering activity in vivo, as 
they can be barriers to bioavailability and efficacy. These factors are influenced by the solid form in 
which the compound of interest resides, whether this be as polymorphs, salts, solvates, co-crystals or 
even incorporated into microspheres [30]. 
Drug compounds can frequently exist in a number of different polymorphs. Ten polymorphs of 
TMZ are covered in the patent literature [31,32], of which four have had X-ray structures solved [33,34]. 
TMZ can easily form a dimer via intermolecular hydrogen bonds between the carboxamide groups 
(Figure 7). It has also been proposed that the energetic preference for the observed conformer can be 
attributed to an intramolecular hydrogen bonding interaction between amide NH and imidazole N7, 
although this shows significant (74°) deviation from linearity [27,33]. 
Figure 7. Dimers seen in Lowe’s crystal structure of TMZ [33]. Strong H-bonds are shown in green. 
 
Stored under the correct conditions, commercial TMZ is relatively stable. However, prolonged 
storage or exposure to humid conditions can accelerate degradation of the prodrug and reduce efficacy. 
Salt formation and crystallisation are widely accepted methods of altering physicochemical properties 
of drug molecules. 
In recent years, a great deal of work has been done, primarily by Babu and co-workers, to 
investigate the co-crystalisation of TMZ with different molecules as a means of enhancing stability and 
solubility. Given the higher stability of TMZ under acidic conditions, Babu et al. reasoned that  
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co-crystallisation with compounds bearing generally-recognised-as-safe (GRAS) carboxylic acid 
groups could act as pH adjusters to inhibit hydrolytic degradation and thus improve aqueous stability. 
Recognising that complexation must be carefully controlled to ensure that the active species is still 
released, they made a number of co-crystals with organic acids which were characterised by powder 
X-ray diffraction and IR before testing (for an example, see Figure 8). As expected, these co-crystals 
all exhibited a stable hydrogen bonding interaction between the acidic group of the co-former and the 
amide group of TMZ. Several co-crystals showed dissolution rates comparable to that of TMZ and 
they all showed a decrease in decomposition rate in pH 7.0 buffer, with a moderate correlation 
between drug half-life and acidity of the co-former. Whereas TMZ would exhibit discolouration after 
just one week at ambient conditions, co-crystals with succinic acid, oxalic acid or salicylic acid 
showed no sign of discolouration or degradation after one year under the same conditions [35]. 
Figure 8. Temozolomide–salicylic acid co-crystal [35]. Strong H-bonds are shown in green. 
 
In a similar vein, Sanphiu, Babu and Nangia have also created a number of co-crystals using GRAS 
carboxamides such as saccharin and caffeine as co-formers [36]. These two co-crystals were more 
stable than other carboxamides used, and indeed temozolomide; in the case of saccharin this can be 
attributed to its acidic nature. However, the stability improvement was less than that seen with 
carboxylic acid co-formers. 
Babu et al. have recently obtained a crystal structure of TMZ hydrochloride in its dihydrate form.  
It is shown that the lattice structure for this crystallisation form contains one neutral TMZ, one 
TMZ·HCl, one H3OCl and three water molecules, with protonation, as expected from previous NMR 
studies [26], occurring at the imidazole N7 of TMZ (Figure 9). The network of hydrogen bonds forms 
a tetrameric TMZ unit which extends into parallel sets of ribbons, connected by strong hydrogen bonds 
to water and chloride ions [27]. Under accelerated humidity conditions, after one week the PXRD plot 
of the hydrochloride salt had reverted to that of neutral TMZ. 
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Figure 9. A tetrameric unit of TMZ in the crystal structure of TMZ·HCl·2H2O [27]. Strong 
H-bonds are shown in green. 
 
Other TMZ complexes include that with cadmium chloride, synthesised by Liu [37]. Appel et al. 
exploited the use cucurbit[n]uril (14), which has previously been shown to improve the solubilty, 
stability and cellular uptake of drug molecules. They formed a 1:1 complex with TMZ, encapsulating 
the drug within the natural cavity of the macrocycle (Figure 10). In doing so, the stability of the 
imidazotetrazine was increased, resulting in a longer half-life (5 h in pH 7.0 buffer, compared with 3 h 
for the control solution of TMZ alone). It was observed that the activity of the drug against 
glioblastoma multiforme (GBM) primary cells was increased, presumably due to the prolonged 
lifetime of TMZ in solution. This may allow increased absorption into cells prior to hydrolysis and 
thus increased exposure to the active drug since MTIC itself does not cross the blood-brain barrier or 
effectively penetrate cells [38]. 
Figure 10. Cucurbit[n]uril (14) and uptake of TMZ into GBM cells [38]. 
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6. Synthesis of Temozolomide and the Imidazotetrazine Core 
The original synthetic strategy towards TMZ and other imidazotetrazines is based on a general 
method for azolotetrazines [39], and involves the coupling of 5-diazoimidazole-4-carboxamide  
(diazo-IC, 10) or its analogues with the relevant isocyanate (Scheme 5). Evidence suggests this occurs 
in a stepwise rather than a concerted mechanism [20,25]. Diazo-IC can be readily prepared on a 
multigram scale from commercially available AIC hydrochloride 4 by treatment under diazotisation 
conditions (NaNO2/HCl), which produces the desired product in yields of 70%–94% [26,40]. 
Incidentally, if acidic conditions are not used in this reaction, AHX is instead furnished as the sole 
product [41]. Cyclisation of diazo-IC to AHX occurs rapidly under basic conditions but also takes 
place more slowly in neutral and acidic media, doing so more readily when light is present [40,42].  
In addition, AHX has been observed as result of imidazotetrazine decomposition [20,25]. 
Early examples of the coupling of diazo-IC with isocyanates were performed in dichloromethane or 
ethyl acetate, keeping the reaction in the dark to avoid UV-promoted decomposition of diazo-IC. 
Although use of these reaction solvents results in clinical grade material, reaction times are very slow 
due to the insolubility of diazo-IC, typically taking several weeks to reach completion [20]. More 
recent synthetic protocols generally employ DMSO as the reaction solvent, giving rise to much faster 
reaction times [26,43]. Attempts using a range of imidazolonium and phosphonium ionic liquids failed 
to improve on the rate, yield or purity of the DMSO reaction [44]. A mixed DMSO–EtOAc solvent has 
also been used to give large amounts of clinical grade TMZ in three days [45]. Isolation of the 
imidazotetrazine products can often be achieved by addition of water or ethyl acetate and collection of 
the resultant precipitate. 
Scheme 5. Initial synthesis of TMZ from AIC·HCl and routes to AHX [20,25,26,40–42]. 
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The stigma associated with the use of methyl isocyanate, following the 1984 Bhopal disaster and 
subsequent near-disappearance of the compound from the market, prompted the development of a 
number of alternative routes to TMZ and thus the imidazotetrazine core structure [47]. The first of 
these approaches was to use a masked methyl isocyanate equivalent (Scheme 6). Wang used 
commercially available isocyanoacetate 15 to synthesise an ester analogue of TMZ (16) by reacting 
with either Diazo-IC or AIC·HCl. This compound was subsequently functionalized via acid 17 to 
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carbonic anhydride 18, converted to activated ester 19 and then subjected to Barton decarboxylation 
conditions to reveal the desired methyl group of TMZ [46]. 
Scheme 6. Masked methyl isocyanate approach to TMZ [46]. 
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Reagents and conditions: (i) Diazo-IC, DMSO, 25 °C (80%) or AIC·HCl, pyridine, DMSO, 20 °C followed 
by NaNO2, 2 M HCl, 0 °C (71%); (ii) 5 M HCl, 45 °C; (iii) Me2CHCH2CO2Cl, N-methylmorpholine;  
(iv) 2-mercaptopyridine-N-oxide, Et3N, í15 °C; (v) Bu3SnH, AIBN (cat.), DMF, hȞ (26%) [46]. 
Alternative masking of the methyl group can be achieved using silicon. TMS protected 
imidazotetrazine derivative 20 was synthesised in 33% yield from the appropriate isocyanate and 
diazo-IC; treatment with TBAF then furnished TMZ (Scheme 7) [48]. 
Scheme 7. TMS deprotection to give TMZ [48]. 
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In addition to the use of alternative isocyanates, routes to imidazotetrazines avoiding the use of 
potentially-explosive diazo-IC were also explored (Scheme 8). The first of these started from AIC·HCl 
but reversed the two steps of the original synthesis to proceed via urea 21. Formation of ureas gives 
high yields however the subsequent imidazotetrazine cyclisation was found to be generally low 
yielding (30%–35% in the case of TMZ under standard conditions), with a significant amount of AHX 
seen as a by-product [47,49]. Alternative routes to urea 21 also obviated methyl isocyanate from this 
process. Reaction of AIC with p-nitrophenyl chloroformate (22) furnished carbamate 23 which was 
treated with methylamine to give the desired urea. A second modification allowed direct formation of 
the urea by carbamoylation of AIC with methylcarbamoyl chloride (24), whereas a related route  
by Turchetta et al. involved the use of N-succinimidyl-N'-methyl carbamate (25) as the carbamoylating  
agent [50]. Exploration of a variety of solvents, nitrosating agents and acids gave the optimum 
imidazotetrazine-forming conditions to TMZ as outlined in Scheme 8. A more recent patent gives 
alternative conditions for diazotisation using LiCl to give TMZ in up to 65% yield [51]. 
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Scheme 8. Routes to TMZ via urea 21 [47,49,50]. 
 
Treatment of ureas 26 with orthoformates rather than nitration gave rise to imidazotriazinones 27 
(Scheme 9). Alternatively, reaction of diazo-IC with ethyl cyanoacetate or ethyl acetoacetate afforded 
regioisomeric imidazotriazinones 29 via unstable hydrazones 28 [25]. These types of heterocyclic 
structures, however, cannot give rise to biological activity in the same manner as the imidazotetrazines. 
Scheme 9. Synthesis of imidazotriazinones [25]. 
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A further alternative to bypass diazo-IC in imidazotetrazine synthesis involved switching the amide 
to a nitrile group (Scheme 10). It was hypothesised that removal of the amide functionality would 
suppress competing formation of unwanted side-product AHX. In fact, the yield from cyclisation of 
this nitrile compound 31 was lower than that obtained using diazo-IC. Following dehydration of AIC 
with phosphorus oxychloride, nitrile 30 was subjected to the standard diazotisation/cycloaddition 
conditions to give TMZ analogue 32 in 44% yield. Reversing these steps offered no improvement as 
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formation of urea 33 was achieved in only 5% yield, resulting in a 1% yield of imidazotetrazine 32 
over the two steps (Scheme 11). 
Scheme 10. Synthesis of TMZ·HCl from diazo-ICN (31) [47]. 
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The acid stability of TMZ allowed hydrolysis of the nitrile group with HCl, restoring the amide 
group and giving the desired product TMZ·HCl in 65% yield for the final step [47]. The yield for this 
hydrolysis has since been improved by Etlin et al. (89%) by lowering the reaction temperature, along 
with a method for subsequent neutralisation of the hydrochloride salt [52]. 
No improvement to the cyclisation was achieved when the ethyl ester urea 34 was subjected to 
nitration conditions; in this case only a 10% yield of tetrazine 35 was observed (Scheme 11). 
Scheme 11. Summary of routes to amide alternatives [47]. 
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Neither nitrile nor ester intermediates 36 are able to undergo competing intramolecular cyclisation 
to give AHX-type compounds. The most likely explanation for the poor yields is therefore that such 
intermediates are sensitive to inductive effects; these side chains may be too electron withdrawing 
compared with the amide of TMZ, thus impeding cyclisation and allowing other degradation pathways 
to manifest. Wang et al. point out subtle reactivity patterns amongst these derivatized intermediates, 
highlighting the complexity in constructing and handling such ring systems [47]. 
A somewhat different approach to TMZ synthesis using an MTIC analogue was taken by Wanner 
and Koomen (Scheme 12) [53]. This route exploits a UV-activated double bond isomerisation of 
Pharmaceuticals 2014, 7 814 
 
 
triazene 40, which triggers spontaneous formation of TMZ. Beginning with 5-nitroimidazole (37), 
functionality is built up stepwise, culminating in condensation of 39 with phenylmethylcarbazate to 
provide the triazene moiety, followed by nitrile hydrolysis to furnish 40 prior to isomerisation. Whilst 
an elegant final step, the synthetic route to this key cyclisation precursor is comparatively lengthy  
vis-à-vis most other syntheses, with TMZ being made in an overall yield of 23% from imidazole 37. 
Scheme 12. Wanner and Koomen’s route to TMZ. 
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Reagents and conditions: (i) HNO3, Ac2O, 85%; (ii) KCN, NaHCO3, MeOH, H2O, rt, 62%; (iii) dihydropyran, 
p-TsOH, EtOAc, 96%; (iv) H2, 10% Pt/C, EtOAc, rt, 1 h; (v) NaIO4 in H2O, EtOAc, 0 °C, 30 min;  
(vi) H2N-N(Me)COOPh, CH2Cl2–AcOH (5:2), rt, 2 h; (vii) TFA–AcOH–MeOH (3:6:10), rt, 5 h, 76% from 
38; (viii) c. HCl–AcOH (2:1), 60–65 °C, 25 min, 74%; (ix) acetone–MeOH (2:1), 366 nm, rt, 1 h, 79% [53]. 
Schering-Plough Corporation has two patented procedures for the potential industrial scale 
synthesis of TMZ. The first of these avoids the handling of both diazo-IC and isocyanates but 
nevertheless has a familiar starting material. Following formation of carbamate 23 from AIC·HCl; this 
activated intermediate was then treated with methyl hydrazine to give hydrazide 41. Finally, periodic 
acid effected an unusual oxidative cyclisation to furnish TMZ (Scheme 13) [54]. 
Scheme 13. Schering-Plough industrial route to TMZ [54]. 
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Their second and more cumbersome route requires construction of the imidazole ring during a 
lengthy route to urea 42. Improved conditions for cyclisation afford imidazotetrazine 43 and acidic 
cleavage of the tert-butyl protecting group finally furnished TMZ (Scheme 14) [55,56]. 
Scheme 14. Schering-Plough alternative route to TMZ [55,56]. 
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For small scale research purposes, coupling of diazo-IC with isocyanates in DMSO remains the 
method of choice for imidazotetrazine construction and offers unrivalled efficiency in terms of atom 
economy. Isocyanates 7 are most commonly formed via Curtius rearrangement of the corresponding 
azide 44. The azides themselves can be constructed by subjecting the hydrazide 45 to diazotisation 
conditions, or by treatment of an activated carbonyl 46 with sodium azide or a carboxylate with dppa 
(diphenylphosphoryl azide) (Scheme 15). Isocyanates are notoriously difficult to handle and purify; 
Curtius rearrangements, as well as urea thermolysis, give access to isocyanates with high purity, a 
factor which has proved to be important in the synthesis of more elaborate imidazotetrazine compounds. 
Scheme 15. Common routes to isocyanates. 
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Various studies have required the synthesis of isotopically labelled TMZ. The pyrolysis of ureas is 
an attractive method for the preparation of volatile isocyanates since pure products are collected via 
distillation [57]; this was exploited in the synthesis of isotopically labelled isocyanates in order to 
assemble 13C/15N-labelled TMZ. Reaction of diphenylcarbamoyl chloride (47) with either 13C- or  
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15N-methylamine gave ureas 48a and 48b, which under thermolysis created 13C- and 15N-methyl 
isocyanate (49a and 49b) respectively (Scheme 16) [26]. This strategy has also been used for a number 
of other isocyanates during the formation of imidazotetrazines [25], including a process scale 
production of TMZ [58]. Access to isocyanates can also be achieved by the pyrolysis of  
4,4'-methylenebis(phenylisocyanate) (50) in the presence of amines (Scheme 17) [59]. 
Scheme 16. Urea pyrolysis to give labelled methylisocyanates [26]. 
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Scheme 17. Thermolysis of 4,4'-methylenebis(phenylisocyanate) (50) [59]. 
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Two other isocyanate-forming methods are demonstrated by Brown et al., who initially attempted 
to synthesise 11C-labelled TMZ exploiting the known intermediate in the TMZ activation pathway, 
MTIC (2), and coupling this with isotopically labelled phosgene [8]. As with previous efforts to effect 
this reaction [47], this was without success. They were able instead to utilise the radiolabelled 
phosgene (51) to rapidly obtain [11C-carbonyl]methyl isocyanate (49c) which was then used in a 
standard coupling reaction, gaining access to [4-11C-carbonyl]TMZ (Scheme 18). 
Scheme 18. Alternative routes to isocyanates used in labelling studies [8]. 
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An alternative synthetic route to the isocyanate employing [11C]iodomethane (52) and silver cyanate 
also allowed access to [3-N-11C-methyl]TMZ. Due to the short half-life (t½ = 20.33 min) of 11C, 
expeditious reactions are necessary in such radiosyntheses; Brown et al. found they were able to use 
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elevated temperatures (100 °C for 10 min rather than room temperature for several hours) to 
significantly reduce reaction time in the coupling of isocyanates 49c/d with diazo-IC (Scheme 18) [8]. 
2-15N-TMZ and [2H3-methyl]TMZ have also been synthesised by the standard method using 
[15N]diazo-IC (from Na15NO2) [26], and [2H3]methyl isocyanate respectively [25], and [6-14C-
imidazole]TMZ has been used in several pharmacokinetic studies [7,60–62]. A summary of positions 
which have been labelled is shown in Figure 11. 
Figure 11. Summary of sites that have been isotopically labelled in TMZ [7,8,25,26,60–63]. 
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7. Synthesis of Structural Analogues 
Various TMZ analogues have been synthesized in efforts to find new, improved anti-cancer agents, 
using a range of methods to alter different parts of its structure. 
7.1. Alternative Cores 
It is clear from the mechanism of action that the tetrazinone ring is crucial for the activity of 
imidazotetrazine anticancer agents, which function via DNA alkylation; the importance of the 
imidazole on the other hand was initially less well understood. Pyrazolo analogues of MTZ and TMZ 
were initially made by Cheng et al., in order to generate agents with lower light sensitivity [64]. Whilst 
MTZ analogue 53 showed excellent antineoplastic activity against leukemia cell lines P388 and 
L1210, the corresponding TMZ analogue 54 was totally inactive [64]. It has, however, shown potency 
in the lymphoblastoid GM892A (MGMTí) cell line [24]. 
Figure 12. Pyrazolo analogues of MTZ and TMZ [64]. 
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A more thorough investigation into fused heterocycle effects has been made by the Cirrincione 
group, who have synthesised a range of alternative bicyclic ring structures related to the 
imidazotetrazines. Coupling isocyanates with diazopyrroles 55 and 2-diazoindoles 56 afforded 
pyrrolo[2,1-d][1,2,3,5]tetrazinones 57 and indolo[2,1-d][1,2,3,5]-tetrazinones 58 respectively  
(Scheme 19) [65,66]. Whereas the latter could be easily made using the standard procedure, the pyrrole 
series required more forcing conditions owing to reduced electrophilicity of the diazo group [65]. 
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Some compounds showed modest activity in a range of cell lines in the NCI60 panel; of those in 
which growth inhibition was observed, GI50 values were generally in the 10–100 ȝM range. Indolo 
compounds 58 as a class were inactive (GI50 > 100 ȝM) [67], whereas pyrrolo compounds 57 showed a 
range of activity (GI50 > 100 ȝM to < 10 nM); the most potent compound in the series had a GI50  
of <30 nM in a number of cell lines. QSAR trends and COMPARE analysis against the standard agents 
database indicated that the mode of action of pyrrolotetrazinones 57 differs from that of the 
imidazotetrazines [68,69]. Interestingly, some analogous triazines 59 and 60 also showed antiproliferative 
activity although as expected, COMPARE data highlighted that these too function by an alternative 
mechanism of action from members of the standard agents database [70,71]. 
Scheme 19. Heteroanalogues of imidazotetrazines [65,66]. 
 
 
Diana and co-workers prepared two series of analogous pyridopyrrolotetrazinones 61 and 62. 
Following construction of the pyrrolopyridine fragments 63 and 64, standard diazotisation and 
coupling protocols gave the desired products. It is worthy of note that coupling with isocyanates was 
found to elicit higher yields when performed under microwave irradiation with greatly reduced 
reaction times (Scheme 20). Three of the compounds 62 showed growth inhibitory activity against a 
limited number of cell lines [72], but none of the compounds 61 tested in the NCI60 panel showed any 
significant activity [73]. 
Scheme 20. Synthesis of pyridopyrrolotetrazinones [72,73]. 
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Two dihydropyrazolotetrazepines 65 were synthesised by Maggio and co-workers (Figure 13); 
however, these compounds were inherently unstable and thus their biological profiles could not be 
evaluated [74]. A number of pyrazolotetrazinones 66 has also been synthesized for use as herbicidal 
agents [75,76]. 
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Figure 13. Unstable tetrazepines [74], and pyrazolotetrazinone herbicidal agents [76]. 
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7.2. 6- and 8-Analogues 
Lunt and co-workers used a variety of alternatively substituted imidazoles 67 and pyrazoles 69 to 
create MTZ analogues 68 and 70 (Scheme 21) [19]. An assessment of the structure–activity 
relationship was first made by alteration of groups in the 6-position (R1). Several compounds were 
made with straight chain and branched alkyl groups of increasing size. Smaller substituents showed 
similar activity to MTZ but more bulky groups appeared to be less cytotoxic which is likely to be due 
to a steric barrier to hydrolysis. 
Scheme 21. Synthesis of 6- and 8-analogues via substituted imidazoles [19]. 
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A large range of analogues with different groups in the 8-position (R2), these mostly being amides 
and sulfonamides, exhibited a more complex structure–activity relationship. Increasing bulk of the 
amide substituent appeared to reduce cytotoxicity; the same trend was seen with sulfamoyl compounds 
but these as a class, along with 8-methylsulfonyl, showed enhanced potency compared with the 
amides. The 8-phenyl, 8-cyano and 8-nitro compounds tested showed no useful in vivo activity. 
Pyrazolotetrazines showed similar trends, but as well as being more complicated to synthesise, showed 
lower potency than the corresponding imidazotetrazines [19]. 
Derivatisation of the 8-position of MTZ and TMZ can be achieved via treatment with 
nitrosylsulfuric acid (formed in situ) to hydrolse the amide moiety to carboxylic acid 71 (Scheme 22). 
Conversion to acid chloride 72 using refluxing thionyl chloride provides the necessary activation for 
selective reaction with nucleophiles, without destructive nucleophilic attack at the crucial endocyclic 
carbonyl. In this manner, large numbers of ester and amide analogues of MTZ 73 have been 
synthesised [77]. These compounds showed a broad range of activity in the TLX5 lymphoma cell line 
but no clear structure–activity relationship could be determined. This acid chloride approach was also 
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utilised by Liu in the construction of a range of TMZ-based amides and esters. Esters were shown to 
have at least 60-fold higher water solubility than TMZ as well as more potent antitumour activity in 
HL-60 leukemia cell line [78]. 
Scheme 22. General synthesis of esters and amides via MTZ acid chloride [78]. 
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Esters and amides can also be achieved directly from carboxylic acid 71 by the use of alkyl halides 
or amines with coupling reagents such as DCC or phosphonium salts [79]. A number of conjugates 74 
with amino acids on MTZ were prepared using this method, employing solid phase synthesis to 
generate longer chain DNA major-groove targeting peptidic analogues (Scheme 23) [45]. Care must of 
course be taken to avoid basic conditions in the presence of imidazotetrazines and with this in mind 
only acid labile groups were utilised for protection of amino acid side chain residues. 
Scheme 23. Synthesis of amides from MTZ carboxylic acid [45]. 
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No significant change in aqueous stability was observed in this set of amide compounds and in vitro 
activity was not sufficiently improved to warrant further investigation. Imidazotetrazines conjugated to 
lexitropsins, a group of known distamycin-derived minor groove DNA binders were also synthesised 
by amide coupling. These conjugates were surprisingly water soluble but showed no enhanced activity. 
Regardless of the nature of the conjugate (major or minor groove targeting), alkylation was always 
seen at guanine-rich sequences in the major groove of DNA [45]. 
This coupling method was used in the synthesis of an assortment of temozolomide alkyl esters, 
thioesters and amides as prodrugs for topical application. Hexyl ester 75 was tested both in vitro and  
in vivo and showed improved dermal permeability compared with that of TMZ as well as demonstrating 
effective anti-melanoma properties (Figure 14) [80]. 
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Wang also synthesized a number of amide/ester linked imidazotetrazines using PyBOP coupling in 
order to explore the dual action of MTZ/TMZ with cephalosporin antibiotic agents, with an aim to 
increase the spectrum of activity of the parent antibiotics (Figure 14) [81]. However, dual action ȕ-lactam 
agents 76 were not as effective as ampicillin against most bacterial strains and little synergistic  
activity was seen. 
Figure 14. TMZ hexyl ester [80], and ȕ-lactam antibiotics [81]. 
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An ethylene glycol linked dimer of TMZ 77 (Scheme 24), synthesised from acid 78 and PEG400 
(79), when administered intravenously showed equal efficacy against glioma cells in vivo compared 
with oral dosing of TMZ. In addition, a mouse xenograft model showed tumour growth inhibition 
comparable to that exhibited by TMZ [82]. 
Scheme 24. Glycol linker dimer [82]. 
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An alternative way to derivatise the 8-position is to convert the carboxamide to a thioamide. 
Hummersone and co-workers used phosphorus pentasulfide and hexamethyldisiloxane to elaborate on 
the 8-position. These thioamides 80 can then be further derivatised to thiazoles 81 by condensation 
with an appropriate Į-bromo ketone 82. Alternatively, conversion of thioamides to carbimidothioates 
83 then reaction with aminoketones 84 gives access to imidazoles 85 (Scheme 25) [83]. 
Oxazoles 86 can similarly be synthesised by treatment of carboxamides, e.g., 1a with Į-bromo 
ketones. Alternatively, reaction of acid chloride 87 with an appropriate amino ketone to form keto 
amides of the form 89 followed by ring closure and dehydration gives regioisomeric oxazoles 91.  
In a similar manner, reaction of carboxylic acids 88 with hydrazides allows construction of oxadiazoles 
92 via 90 (Scheme 26). A large number of these 8-substituted compounds was found to have effective 
biological activity, even in cell lines that have active MGMT; many compounds showed GI50  
values <45 ȝM (compared to 45.6 ȝM for TMZ) in SNB19V (MGMTí) and <70 ȝM (compared to 
526.3 ȝM for TMZ) in SNB19M (MGMT+) [83]. 
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Scheme 25. Formation of thiazoles and imidazoles [83]. 
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Scheme 26. Construction of oxazoles and oxadiazoles [83]. 
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7.3. 3-Analogues 
The 3-substituent in imidazotetrazine compounds is crucial as this is the group that controls 
reactivity of the imidazotetrazine and will also be delivered and subsequently bonded to DNA. A large 
number of 3-N-substituted imidazotetrazines has been synthesised, bearing a variety of functionalised 
alkyl groups as well as alkyl-linked aromatics and heterocycles [25,84,85]. These have been 
constructed mostly using isocyanate methods. The effects of steric hindrance on this coupling reaction 
with diazo-IC (8) are evident; benzyl isocyanate gives 90% yield of 1o [43], whereas (R)- and  
(S)-1-phenylethyl isocyanate after 16 h afford imidazotetrazines 1p and 1q in 56% and 65% yield 
respectively. Somewhat surprisingly, reaction with, Į-dimethylbenzyl isocyanate does furnish the  
gem-dimethyl analogue 1r, albeit it in a yield of only 3% after 16 h reaction time (Scheme 27) [84,85]. 
A more recent development in imidazotetrazine synthesis employs the intermediate, 
nortemozolomide (93). The route to 93 uses diazo-IC (10) and glycine-derived isocyanate 94, itself 
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formed via azide displacement of the anhydride resulting from reaction with Boc-glycine (95) and 
ethyl chloroformate (96), and subsequent Curtius rearrangement. Following imidazotetrazine 
formation, Boc-deprotection of 96 leads to spontaneous elimination of formaldehyde imine, thus 
resulting in formation of nortemozolomide (Scheme 28) [86,87]. This imidazotetrazine compound 
opens up scope for not only the synthesis of TMZ but also creates opportunities for alternative routes 
to 3-N-substituted analogues. 
Scheme 27. Example of steric effects on the diazo-IC–isocyanate coupling reaction [43,84,85]. 
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Scheme 28. Synthesis of nortemozolomide [86,87]. 
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Methylation of 93 to give TMZ was achieved by Cousin et al., in 61% yield by deprotonation with 
sodium hydride and subsequent quenching of the anion with an excess of methyl iodide in DMF.  
An O-methylated side-product was also detected, suspected to be 98; alteration of base had little effect 
on the outcome of the reaction but less side-product was obtained when the reaction was performed at 
lower temperatures (í20 °C) [87]. During the course of their [13C]-and [11C]-labelled TMZ syntheses, 
Moseley and co-workers determined that sodium hydride was the optimum base for methylation of 
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nortemozolomide in order to reduce 8-N-methylation. However, they observed that the reaction is 
sensitive to the amount of base and found that with [13C]-methyl iodide, excess NaH resulted in 
exclusive 8-N-methylation to give 99 and that substoichiometric quantities favoured 3-N-methylation 
(Scheme 29) [63]. 
Scheme 29. Methylation of nortemozolomide [63,87]. 
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The derivatization of 93 using a number of alkylating agents was also investigated. The scope was 
shown to be limited, as alkyl halides with bulky or electron withdrawing substituents failed to yield the 
desired products. The benzyl derivative 1o was obtained under Mitsunobu conditions whereas 
hydroxymethyl compound 1s was formed from simple treatment of 93 with formaldehyde (Scheme 
30). This alcohol itself was next probed as a gateway to diversification. Exposure to acid gave only 
ring decomposition products rather than the anticipated iminium species 102 which it was envisioned 
could have provided access to ethers and thioethers. On the other hand, treatment of 1s with DBU and 
trapping with electrophiles provided alternative, if less efficient conditions for access to simple 
alkylated systems, presumably via anion 100. Alcohol 1s is also accessible in high yield  
from SEM protected nortemozolomide 101 via BF3 etherate deprotection, albeit with some BF3 
contamination [84,87]. 
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Scheme 30. Alkylation of nortemozolomide [84,87]. 
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8. Design of MGMT/MMR-Independent Anti-Cancer Agents 
The principal constraints on TMZ efficacy are the dependence on MMR and resistance caused by 
MGMT, the result of which is that the number of tumours able to respond to TMZ therapy is limited; 
current efforts in the design of new analogues seek to bypass these limitations. 
Although much attention has been paid to the modification of the 8-substituent and exploring the 
effects of targeting ligands attached at this position, it is actually the 3-subsituent that generates the 
pharmacological activity of the imidazotetrazines. Recent efforts to modify tumour response to TMZ-type 
drugs have focused on this position. Key to rationally altering the 3-substituent and the biological 
activity is a full appreciation of the role of the 3-substituent in the imidazotetrazine mechanism of 
activation and reactivity. 
One approach towards achieving this is to modify the 3-substituent of the imidazotetrazine such that 
the group transferred to DNA GO6 sites is a poor substrate for MGMT and thus is not susceptible to 
recognition or DNA repair by the protein. A family of alkylated guanine molecules 103 with polar or 
ionisable O6 substituents has been synthesised and demonstrated resistance to MGMT cleavage 
(Figure 15) [88]. A number of imidazotetrazine 3-N-derivatives bearing such types of substituents 
(e.g., 1w and 1x) has demonstrated MGMT- and MMR-independent activity; several cell lines that are 
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resistant to TMZ, whether due to high levels of MGMT or MMR mutation/deficiency, have shown 
sensitivity to these new compounds [85,89]. 
Figure 15. Compounds resistant to MGMT effects [85,88,89]. 
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Another approach is to subtly shift the mode of action, which has been achieved by embracing a 
neighbouring group participation (NGP) mechanism to alter the behaviour of the active species 
resulting from prodrug release. 
8.1. Introduction to NGP Analogues 
Earlier, the aqueous chemistry of the early imidazotetrazines was discussed (vide supra, Section 3), 
summarised in Scheme 31. The important lesson here is that for a drug to elicit a biological response, 
fine tuning of the latent electrophile is required. Firstly so that unproductive side-reactions, such as 
inactivation by elimination, hydrolysis or rearrangement, are disfavoured. More subtly, it is also 
important that the ultimate electrophile has sufficient aqueous lifetime to locate an appropriate reaction 
site on DNA. Stabilisation of diazonium ions 5, 5b, by either equilibration with diazomethane (6) or 
involvement of the neighbouring chlorine atom to form a chloronium intermediate 12, appears 
adequate to ensure useful pharmacological activity. In contrast, ethyl diazonium (5c) is not stabilised 
by equilibration with the diazo form but is susceptible to elimination which provides a “dead end” to 
the sequence of reactive intermediates. 
Scheme 31. Summary of alkyldiazonium ions derived from early imidazotetrazines. 
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Control of the reactive intermediates has been achieved using neighbouring group participation 
mechanisms, inspired in part by the chloronium ion of MTZ and the aziridinium intermediates 
generated by nitrogen mustard prodrugs. Moreover, bisimidazotetrazines were designed that combined 
two imidazotetrazines to form potential DNA crosslinking agents. The first examples used sulfur as the 
heteroatom, e.g., 104, 105 and led to both effective DNA alkylation (Figure 16), and activity in the 
NCI60 panel [90]. The good reactivity with DNA was consistent with the generation of episulfonium 
ions 106 which are relatively long-lived intermediates in aqueous systems (Scheme 32) [91]. Whilst 
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demonstrating the validity of the design principles, further development of the thioether and disulphide 
linked compounds was disfavoured as NCI COMPARE analysis indicated close relationships with 
existing agents such as thiotepa, chlorambucil and uracil mustard (p > 0.8) [92]. 
Figure 16. (Left) Comparison of reaction of TMZ, MTZ and a disulphide-linked dimer 105 
with DNA showing the enhanced reactivity of the episulphonium prodrug, sites of DNA 
alkylation detected by the Taq DNA polymerase stop method (adapted from reference [90]); 
(Right) Reaction of Aziridinium Prodrugs (DP86 and DP68, 107a and 108a) showing the 
increased reactivity of the bisimidazotetrazine. Sites of GN7 alkylation on the upper strand 
of pBR322 DNA detected by the piperidine cleavage method. Arrows indicate the position 
and sequence context of the alkylated guanines. Adapted from reference [93]. 
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Scheme 32. Generation of episulfonium ions from a sulfur-linker dimer [90]. 
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Potential aziridinium ion precursors were attractive as these are reactive intermediates of proven 
clinical utility, being found widely in, or generated by, synthetic and natural product anti-tumour drugs 
and prodrugs so may be expected empirically to display suitable pharmacokinetics. 
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8.2. Synthesis of Novel N-Linked Imidazotetrazine Dimers 
This new class of compounds employed nitrogen as the heteroatom controlling the cascade of 
reactive intermediates in a manner analogous to the nitrogen mustard drugs 107 (Figure 17). These 
anticancer agents are DNA cross-linkers which react via aziridinium ions 108; these are ring opened 
during nucleophilic substitution reactions with groups on DNA, principally N7 of guanine residues. 
Figure 17. Nitrogen mustards, resulting aziridinium ions and novel imidazotetrazine dimers. 
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These novel N-linked dimers 109 were rationally designed as acid-stable precursors to aziridinium 
ions, to combine the useful pharmacokinetic properties of the imidazotetrazines with the proven 
clinical utility of DNA cross-linkers. By exploiting preferential GN7 alkylation (70% for TMZ), as 
opposed to the mere 5% alkylation at GO6, an efficiency gain was sought; moreover, the requirements 
for MMR and absence of MGMT may be negated. 
Scheme 33. Synthesis of N-linked dimers and momomers from diisocyanates and isocyanates [93–95]. 
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Synthesis of these dimer compounds 109 was via diisocyanates, an approach that had already 
proved successful in the construction of dimeric imidazotetrazines [25,45]. A family of monomeric 
imidazotetrazines 110 with aminoethyl side chains has been similarly prepared. The required substrates 
were obtained from conjugate addition of primary and secondary anilines 111 with methyl acrylate 
followed by functional group interconversion to give diisocyanates 112 and isocyanates 113 
respectively (Scheme 33) [93–95]. 
Imidazotetrazine rings cannot be closed in the presence of tertiary amines unless the nucleophilic 
centre is deactivated. This can be achieved through the use of anilines or by N-Boc protection; these 
techniques also serve the purpose of preventing undesired cyclisation of β-aminoisocyanates 114 to 
cyclic ureas 115 (Scheme 34) [95]. It is worthy of note that an acetate group is insufficiently electron 
withdrawing for N-deactivation. Little difference in reaction yield was seen between secondary and 
tertiary anilines and Boc-aniline isocyanates 113 to give 110. 
Scheme 34. Cyclisation of ȕ-aminoisocyanates. 
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8.3. Properties and Activity of N-Linked Compounds 
Both classes of new compound show similar hydrolysis kinetics to TMZ, with almost identical  
half-lives at pH 7.4 and pH 8.0; acid stability is still robust although not as pronounced as for TMZ [93]. 
An isotopically labelled version of monomer 110a was prepared for mechanism studies using 
enriched 13C(2)-acrylate. On exposure to D2O phosphate buffer (pD 7.8), a mixture of phosphate and 
alcohol (hydrolysis) products 116 was observed. From 13C-NMR studies it could be seen that there was 
a 4% excess of the alcohol 116a resulting from direct hydrolysis, yet amongst the remaining 96% there 
was a complete scrambling of the labelled centre, thus proving the formation of an aziridine 
intermediate 117 (Scheme 35) [93]. 
Scheme 35. Aziridinium release [93]. 
N N
N
N
N
O
O
H2N
N*
N
N*
N
N
*
N*
DO
N
*
X
96%
4%
N
*X
X = OD/OPO3
1:1
[13C]110a
116
116a
117
Nuc-
D2O
D2O
 
Pharmaceuticals 2014, 7 830 
 
 
Reaction of 109a and 110a with DNA in a piperidine cleavage assay showed that alkylation sites 
were identical to those obtained with melphalan. In this assay, dimeric compound 109a was more 
reactive than monomer 110a and showed reactivity with DNA equivalent to melphalan (Figure 16) [93]; in 
whole cells, dimer 109a showed DNA crosslinking activity equivalent to melphalan [96]. 
Both dimers 109 and monomers 110 showed promising in vitro anti-cancer activity. Preliminary 
screening was undertaken against an MGMT and MMR-proficient cell line (A2780) and the associated 
MMR-deficient A2780-cp70; MGMT was inactivated with PaTrin2 in order to evaluate both MMR 
and MGMT dependence. Pleasingly, members of both classes of compound showed anti-proliferative 
activity, regardless of MGMT and MMR status of the cell lines tested. The monofunctional agents 
showed activity equivalent to MTZ, whereas the bifunctional agents showed significantly greater 
potency than MTZ [95]. 
Figure 18. Effect of electron-withdrawing capabilities of substituent X on the activity of 
aniline dimers 109 [95]. The differences between sets of lines indicate the limited 
MMR/MGMT effects. 
 
Probing more deeply into the in vitro SAR of the aniline dimers 109 showed a trend in Hammett 
constant vs. IC50; with the exception of the 4-methoxy derivative, the more electron-donating the 
aniline substituent, the better the activity (Figure 18). This shows a clear link between electronics of 
the 4-subtituent and pharmacological activity. This can be rationalised by electron donation providing 
enhanced formation and stability of the aziridinium alkylating agent; the anomalous methoxy group on 
the other hand potentially increases basicity too much so that appreciable protonation of the aniline 
occurs, thus reducing nucleophilicity. 
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Table 2. Results of Matrix COMPARE (P values) for NCEs 109c–e, 110d, with selected 
standard agents. DTIC, 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (3); MEL, 
melphalan; CHB, chlorambucil; BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea; CCNU,  
N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea; CP, cisplatin; Data from reference [95]. 
 109c 109d 109e 110d MTZ DTIC MEL CHB BCNU CCNU CP
109c 1 0.92 0.92 0.83 0.35 0.72 0.4 0.33 0.32 0.06 0.32
109d 0.92 1 0.81 0.79 0.38 0.64 0.36 0.29 0.27 0.05 0.35
109e 0.92 0.81 1 0.77 0.46 0.71 0.59 0.53 0.45 0.10 0.42
110d 0.83 0.79 0.77 1 0.42 0.62 0.35 0.33 0.25 0.08 0.27
Moreover, NCI screening data confirmed the lack of relationship between MGMT, MMR and 
efficacy. Matrix COMPARE analysis showed the distinctiveness of these compounds against other 
aziridinium/diazonium-releasing or crosslinking agents such as MTZ, the nitrosoureas, nitrogen 
mustards and cisplatin (Table 2). 
9. Conclusions 
The imidazotetrazine prodrugs are an interesting class of pharmaceutically active compounds.  
The original synthetic strategy towards the bicyclic imidazotetrazine core employed coupling of  
diazo-IC with isocyanates; the driving forces for alternative syntheses were based around the stigma 
and lack of availability of methyl isocyanate as well as avoidance of potentially explosive diazo-IC. 
Ultimately, however, none of the procedures have bettered the initial route and this remains the 
preferred method for laboratory scale synthesis. 
Ring opening follows two mechanisms, the retro-cycloaddition and hydrolytic prodrug activation 
mechanism. The latter occurs in two steps: hydrolysis of the imidazotetrazine ring followed by  
acid-mediated release of alkyl diazonium ions. The mechanism and kinetics of this prodrug activation 
and thus the circulating half-life are determined by the 3-substituent of the imidazotetrazine.  
The nature of this group plays a huge role as it also ultimately determines the biological response.  
In addition to controlling prodrug activation, controlling the reactivity of the released electrophile is of 
vital importance to allow reaction with DNA. 
Response of a tumour to TMZ treatment is dependent on two factors: absence of MGMT, the 
protein which results in inherent resistance, and presence of MMR, the actions of which ultimately 
lead to cell death. In addition to these constraints, it is only a minor proportion of DNA alkylation  
(5% on GO6) which actually results in the anti-tumour response. Recent efforts to combat MGMT 
resistance have focused on compounds which create adducts unrecognisable by MGMT or those which 
instead are able to elicit a pharmacological response from GN7 alkylation. Moreover, the need for a 
non-mutagentic TMZ derivative is urgent, now that the molecular details of the relationship between 
TMZ-induced mutation and the evolution of aggressive, drug resistant tumour regrowth, following 
initial good response to therapy, has been established [97]. 
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